Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September

/PRNewswire/ -- Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late...

Related Keywords

Germany ,London ,City Of ,United Kingdom ,Boston ,Massachusetts ,United States ,Jonas Dyhrfjeld Johnsen ,Care Research ,Human Hearing Development Impacts Preclinical Efficacy ,National Institute For Health ,Translational Hearing Research Group ,Hearing Research Center Department Of Otolaryngology ,Trends In Drug Development For Age ,University College London Ear Institute ,Royal National Institute For Deaf People ,Therapeutics Gmbh ,Acousia Therapeutics ,Annual Inner Ear Disorders Therapeutics Summit ,Preclinical Study Design ,Enhancing Probability ,Drug Development ,Age Related Hearing ,Chief Development Officer ,Chosen Animal Model ,Lessons Learned ,Locally Administered ,Therapeutics Summit ,Royal National Institute ,Deaf People ,National Institute ,Hearing Research Center ,Neck Surgery ,Inner Ear Biology Workshop ,Drug Candidate Uniquely Suited ,Acousia Therapeutics Gmbh ,